Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
Authors
Keywords
Memantine, Rivastigmine, Tacrine, Galantamine, Cognitive Enhancer
Journal
Alzheimers Research & Therapy
Volume 6, Issue 4, Pages 37
Publisher
Springer Nature
Online
2014-07-03
DOI
10.1186/alzrt269
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical development success rates for investigational drugs
- (2014) Michael Hay et al. NATURE BIOTECHNOLOGY
- Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease
- (2013) Paul S. Aisen et al. NATURE REVIEWS DRUG DISCOVERY
- Monetary Costs of Dementia in the United States
- (2013) Michael D. Hurd et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model†
- (2012) Christopher Hyde et al. AGE AND AGEING
- Drug pipeline in neurodegeneration based on transgenic mice models of Alzheimer's disease
- (2012) Chaoyun Li et al. AGEING RESEARCH REVIEWS
- Pathogenesis and Disease-modifying Therapy in Alzheimer's Disease: The Flat Line of Progress
- (2012) Rudy J. Castellani et al. ARCHIVES OF MEDICAL RESEARCH
- Alzheimer's therapeutics: Continued clinical failures question the validity of the amyloid hypothesis—but what lies beyond?
- (2012) Kevin Mullane et al. BIOCHEMICAL PHARMACOLOGY
- The Usefulness and Challenges of Transgenic Mouse Models in the Study of Alzheimers Disease
- (2012) Donna M. Wilcock CNS & Neurological Disorders-Drug Targets
- Was Phenserine a Failure or Were Investigators Mislead by Methods?
- (2012) Robert E. Becker et al. Current Alzheimer Research
- Increasing the success rate for Alzheimer's disease drug discovery and development
- (2012) Robert E Becker et al. Expert Opinion on Drug Discovery
- Alzheimer’s disease therapeutic trials: EU/US task force report on recruitment, retention, and methodology
- (2012) B. Vellas et al. Journal of Nutrition Health & Aging
- Animal systems in the development of treatments for Alzheimer's disease: challenges, methods, and implications
- (2012) Jonathan J. Sabbagh et al. NEUROBIOLOGY OF AGING
- Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease
- (2012) Robert Howard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Qualified kidney biomarkers and their potential significance in drug safety evaluation and prediction
- (2012) Hong-Guang Xie et al. PHARMACOLOGY & THERAPEUTICS
- The Database for Aggregate Analysis of ClinicalTrials.gov (AACT) and Subsequent Regrouping by Clinical Specialty
- (2012) Asba Tasneem et al. PLoS One
- Advances in the pathogenesis of Alzheimer's disease: a re-evaluation of amyloid cascade hypothesis
- (2012) Dong Suzhen et al. Translational Neurodegeneration
- Evaluation of Drugs With Specific Organ Toxicities in Organ-Specific Cell Lines
- (2011) Zhiwu Lin et al. TOXICOLOGICAL SCIENCES
- Globalization of Alzheimer's disease clinical trials
- (2011) Jeffrey Cummings et al. Alzheimers Research & Therapy
- What Can Be Inferred from the Interruption of the Semagacestat Trial for Treatment of Alzheimer's Disease?
- (2010) Jeffrey Cummings BIOLOGICAL PSYCHIATRY
- Report of the task force on designing clinical trials in early (predementia) AD
- (2010) P. S. Aisen et al. NEUROLOGY
- Of Mice and Men
- (2009) Hugo Geerts CNS DRUGS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More